Zai Lab takes a second punt on MediLink
And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.
In vivo Car-T gains traction
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
Gilead and Galapagos's conscious uncoupling
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
Avenzo follows Bristol’s lead
The private group taps DualityBio for an EGFR x HER3 ADC.
Ideaya's conjugate journey continues
The synthetic lethality specialist licenses in its second ADC in six months.
Elevation brings Synaffix on board in HER3
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
ASH 2024 – J&J reveals more about Lava's secret sauce
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
